Table 3.
Study | <0.76 | 0.76–1.00 | ≤ 1.00 | Factors | |
---|---|---|---|---|---|
Sentinel node | Bedrosian et al35* | 1/40 (2.5%) | 3/31 (9.7%) | 4/71 (5.6%) | VGP, no other |
Bleicher et al34 | 2/118 (1.7%) | 6/154 (3.9%) | 8/272 (2.9%) | Age, incomplete biopsy | |
Jacobs et al44 | 1/NR | 1/NR | 2/63 (3.2%) | ||
Kesmodel et al43 | 1/91 (1.1%) | 8/90 (8.9%) | 9/181 (5.0%) | MR, Br, gender | |
Lowe et al45 | 2/NR | 1/NR | 3/46 (6.5%) | Clark ≥ III | |
Nahabedian et al51 | 0/NR | 2/NR | 2/24 (8.3%) | ||
Oliveira Filho et al46 | NR | NR | 6/77 (7.8%) | ulceration, MR, VGP | |
Puleoet al41 | NR | 20/409 (4.9%) | NR | None predictive | |
Wong et al39 | 0/109 | 8/114 (7.0%) | 8/223 (3.6%) | None predictive | |
Stitzenberg et al36 | 3/NR | 3/NR | 6/146 (4.1%) | None predictive | |
Hershko et al37 | 2/NR | 3/NR | 5/64 (7.8%) | Age | |
Morton et al30 | NR | NR | 34/465 (7.3%) | ||
| |||||
Subtotal | 3/325 (0.94%) | 42/767 (5.5%) | 83/1561 (5.3%) | ||
| |||||
Clinical recurrence | Morton et al30 | NR | NR | 238/1979 (12.0%) | |
Kalady et al50 | NR | NR | 38/1082 (3.5%) | ||
Massi et al52 ** | 8/174 (4.6%) | 17/113 (15%) | 25/287 (8.7%) | TIL | |
Karakousis et al49 | 21/684 (3.1%) | 17/198 (8.6%) | 38/882 (4.3%) | male,<60,axial | |
Corsetti et al48 | 0/NR | 5/NR | 5/68 (7.4%) | Median TTR 52mo | |
Schmid-Wendtner et al53 | 37/2301 (1.6%) | NR | NR | male, ALM or LMM | |
McKinnon et al54 | NR | NR | NR | TTR 49.8mo | |
Woods et al47 | 5/400 (1.3%) | NR | NR | 2.8% total recur | |
Naruns et al55 | 28/649 (4.3%) | NR | NR | male, regression | |
Subtotal | 99/4208 (2.35) | 17/198 (8.6) | 319/4011 (8.0%) | ||
| |||||
TOTAL | 102/4533(2.3%) | 59/965 (6.1%) | 402/5572 (7.2%) |
VGP, vertical growth phase; MR, mitotic rate; Br, Breslow; NR, not reported; TTR, time to recurrence; TIL, tumor-infiltrating lymphocytes; ALM, acral lentigenous melanoma; LMM, lentigo maligna melanoma
These patients also in Kesmodel et al,43 not duplicated in total figures.
up to 1.5 mm included, not included in total figures.